

IN THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Please cancel claims 2, 5-8, 13, 17-25, 27-30, 32, and 35-39 without prejudice to their presentation in another application; and amend claim 9.

STATUS OF CLAIMS

1-8. (canceled)

9. **(currently amended)** A method of delivering a protein to a lymphnode of an individual comprising ~~the steps of:~~

- a) identifying said lymphnode that is to have protein delivered to;
- b) locating a site on said individual's body that is proximal to said lymphnode;
- c) administering to said individual at said site, a DNA molecule comprising a nucleotide sequence that encodes said protein, wherein said DNA molecule is a plasmid and wherein said DNA molecule is operably linked to a secretion signal, a macrophage-specific promoter and a polyadenylation signal that are functional in a macrophage cell, wherein said macrophage specific promoter is from a human gene selected from the group consisting of a M-CSFR promoter, a CD156 promoter, a catalase promoter, a p73 promoter, and an FcγRI promoter;

wherein said DNA molecule is taken up by a macrophage cell where said nucleotide sequence is expressed to produce said protein in said macrophage cell, and said macrophage cell drains to said lymphnode, and delivers said protein in said lymphnode.

10. **(original)** The method of claim 9 wherein said DNA molecule is administered by a route of administration selected from the group consisting of: intradermal, subcutaneous, intraperitoneal, intramuscular, and oral.

11-13. (canceled)

14. **(original)** The method of claim 9 wherein said polyadenylation signal is selected from the group consisting of: an SV40 polyadenylation signal and a bovine growth hormone polyadenylation signal.

15. **(original)** The method of claim 9 wherein said DNA molecule is administered with a composition which facilitates uptake of said DNA molecule by a cell.

16. **(original)** The method of claim 9 wherein said DNA molecule is administered with bupivacaine.

17-33. **(canceled)**

34. **(previously presented)** The method of claim 9 wherein said DNA molecule is administered by intramuscular administration.

35-39. **(canceled)**